Equities

Shenzhen Neptunus Interlong Bio-technique Co Ltd

Shenzhen Neptunus Interlong Bio-technique Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)0.146
  • Today's Change0.00 / 0.00%
  • Shares traded210.00k
  • 1 Year change-9.32%
  • Beta0.3035
Data delayed at least 15 minutes, as of Sep 19 2024 08:26 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments382350311
Total Receivables, Net290277231
Total Inventory205203158
Prepaid expenses436540
Other current assets, total----0
Total current assets921895740
Property, plant & equipment, net286301309
Goodwill, net639797
Intangibles, net122110116
Long term investments10.003030
Note receivable - long term------
Other long term assets------
Total assets1,4161,4481,308
LIABILITIES
Accounts payable14911496
Accrued expenses------
Notes payable/short-term debt8283101
Current portion long-term debt/capital leases3.815.103.94
Other current liabilities, total131211134
Total current liabilities366413335
Total long term debt3.774.480.62
Total debt9093106
Deferred income tax292526
Minority interest108121115
Other liabilities, total0.590.590.94
Total liabilities507564478
SHAREHOLDERS EQUITY
Common stock168168168
Additional paid-in capital555555555
Retained earnings (accumulated deficit)186161107
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity908884830
Total liabilities & shareholders' equity1,4161,4481,308
Total common shares outstanding1,6781,6781,678
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.